Cultrex RGF Basement Membrane Extract, Type 2 3533-001-02 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemCultrex RGF Basement Membrane Extract, Type 2
CompanyR&D Systems, a Bio-Techne Brand
Price $63.00Supplier Page View Company Product Page
Catalog Number3533-001-02
Size1 mL
ApplicationsBioactivity
Format12 - 18 mg/mL
TypeBasement Membrane Extract
StorageProduct is stable for a minimum of 3 months from date of shipment when stored at -20 °C in a manual defrost freezer. For optimal stability, store at -80 °C. Avoid freeze-thaw cycles. Storage Buffer: Dulbecco’s Modified Eagle’s medium without phenol red, with 10 ug/ml gentamicin sulfate. Sterility Testing: PathClear® - Negative by PCR test for mycoplasma; 17 bacterial and virus strains typically included in mouse antibody production (MAP) testing, plus 13 additional murine infectious agents including LDEV, for a total of 31 organisms and viruses. No bacterial or fungal growth detected after incubation at 37 °C for 14 days following USP sterility testing guidelines

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancerbioRxiv : the preprint server for biologySeptember 8, 2025Sheehan C, Hu L, Cognet G, Croley G, Nguyen TT, Thomas-Toth A, Agovino D, Jonker PB, Sadullozoda M, Ziolkowski LM, et al.μL domes of Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2, Pathclear (R&D Systems, 3533–001-02) into 24-well plates and covered with human complete medium (hCPLT, according to Boj et al. and Driehuis

(2) Merging metabolic modeling and imaging for screening therapeutic targets in colorectal cancerNPJ Syst Biol ApplJanuary 28, 2025Niki Tavakoli, Emma J. Fong, Abigail Coleman, Yu-Kai Huang, Mathias Bigger, Michael E. Doche, Seungil Kim, Heinz-Josef Lenz, Nicholas A. Graham, Paul Macklin, et al.Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2 (BME; R&D Systems, Minneapolis, MN; 3533-001-02), and droplets of 60 μL were plated onto 24-well plates. The plates were allowed to slightly gel at

(3) Cell free supernatants of Bifidobacterium adolescentis and Bifidobacterium longum suppress the tumor growth in colorectal cancer organoid modelScientific reportsJanuary 6, 2025Kim MJ, Song MH, Ji YS, Park JW, Shin YK, Kim SC, Kim G, Cho B, Park H, Ku JL, et al.

(4) Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast CancerCancer researchOctober 1, 2024Hillis AL, Martin TD, Manchester HE, Högström J, Zhang N, Lecky E, Kozlova N, Lee J, Persky NS, Root DE, et al.

(5) RET overexpression leads to increased brain metastatic competency in luminal breast cancerJNCI: Journal of the National Cancer InstituteOctober 1, 2024Petra Jagust, Aoibhin M Powell, Mihaela Ola, Louise Watson, Ana de Pablos-Aragoneses, Pedro García- Gómez, Ramón Fallon, Fiona Bane, Mona Heiland, Gareth Morris, et al.Cultrex Reduced Growth Factor Basement Membrane Matrix, type 2 (Trevigen/Bio-Techne, Minneapolis, MN; No. 3533-001-02) in organoid media (6,32). Pharmacological agent LOXO-292 (selpercatinib, gifted from Loxo-Oncology,

(6) Merging Metabolic Modeling and Imaging for Screening Therapeutic Targets in Colorectal CancerbioRxiv : the preprint server for biologySeptember 22, 2024Tavakoli N, Fong EJ, Coleman A, Huang YK, Bigger M, Doche ME, Kim S, Lenz HJ, Graham NA, Macklin P, et al.Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2 (BME; R&D Systems, Minneapolis, MN; 3533-001-02) and droplets of 60μL were plated onto 24-well plates. The plates were allowed to slightly gel at room

(7) Protocol to create isogenic disease models from adult stem cell-derived organoids using next-generation CRISPR toolsSTAR ProtocolsSeptember 20, 2024Martina Celotti, Lucca L.M. Derks, Johan van Es, Ruben van Boxtel, Hans Clevers, Maarten H. Geurts,Thermo Fisher Scientific,D1306 OptiMEM,Thermo Fisher Scientific,11058-021 "Basement membrane extract (BME), type II",R&D Systems,3533-001-02 Hygromycin B Gold solution 100 mg/mL,InvivoGen,ant-hg-1 Nutlin-3 (10 mM stock),Sigma,N6287 Q5 High-fidelity DNA polymerase

(8) Biodegradation of hydroxylated boron nitride nanoplatelets, their toxic effect and drug delivery application†RSC AdvancesAugust 16, 2024Kanwal Asif, Md. Mahbubur Rahman, Andrea Augusto Sfriso, Salvatore Parisi, Vincenzo Canzonieri, Isabella Caligiuri, Flavio Rizzolio, Muhammad Adeelin a Cultrex growth factor-reduced Basement Membrane Extract (BME), Type2 (R&D Systems Catalog no: 3533-001-02, Milan, Italy) and cultured in 24 well plates. Then, 450 μL of the organoid medium was added following

(9) NF-κB inhibitor alpha controls SARS-CoV-2 infection in ACE2-overexpressing human airway organoidsScientific reportsJuly 4, 2024Simoneau CR, Chen PY, Xing GK, Hayashi JM, Chen IP, Khalid MM, Meyers NL, Taha TY, Leon KE, Suryawanshi RK, et al.

(10) Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6Mol Cancer TherJune 4, 2024Eric N. Aguilar, Satish Sagar, Brandy R. Murray, Christabelle Rajesh, Eric K. Lei, Sarah A. Michaud, David R. Goodlett, Thomas C. Caffrey, Paul M. Grandgenett, Benjamin Swanson, et al.previously (23). Organoids were routinely cultured in domes of Cultrex RGF-BME, Type 2 (R&D Systems, # 3533–001-02) in Human Pancreas Medium [DMEM/F12 supplemented with 15 mM HEPES, GlutaMAX™, 1% penicillin/streptomycin,

(11) Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6Molecular Cancer TherapeuticsJune 4, 2024Eric N. Aguilar, Satish Sagar, Brandy R. Murray, Christabelle Rajesh, Eric K. Lei, Sarah A. Michaud, David R. Goodlett, Thomas C. Caffrey, Paul M. Grandgenett, Benjamin Swanson, et al.previously (23). Organoids were routinely cultured in domes of Cultrex RGF-BME, Type 2 (R&D Systems, # 3533–001-02) in Human Pancreas Medium [DMEM/F12 supplemented with 15 mM HEPES, GlutaMAX™, 1% penicillin/streptomycin,

(12) Colonic crypt stem cell functions are controlled by tight junction protein claudin‐7 through Notch/Hippo signalingAnnals of the New York Academy of SciencesMay 1, 2024Amna N. Naser, Tiaosi Xing, Rodney Tatum, Qun Lu, Philip J. Boyer, Yan‐Hua Chenwere mixed with reduced growth factor basement membrane matrix type 2 (R&D Systems; catalog number 3533-001-02) and seeded at 10 crypts/μL matrix in 96-well plates. The colonoid culture medium was overlaid at a

(13) Silver nitroprusside as an efficient chemodynamic therapeutic agent and a peroxynitrite nanogenerator for targeted cancer therapiesJournal of advanced researchFebruary 1, 2024Asif K, Adeel M, Rahman MM, Sfriso AA, Bartoletti M, Canzonieri V, Rizzolio F, Caligiuri I.resuspended in Cultrex growth factor-reduced Basement Membrane Extract (BME), Type2 (R&D Systems Cat. # 3533–001-02, Milan, Italy) and seeded in 24 multi wells. After solidification of the hydrogel, 450 μl of organoid

(14) Human conjunctiva organoids to study ocular surface homeostasis and diseaseCell stem cellFebruary 1, 2024Bannier-Hélaouët M, Korving J, Ma Z, Begthel H, Giladi A, Lamers MM, van de Wetering WJ, Yawata N, Yawata M, LaPointe VLS, et al.

(15) Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical PyroptosisJournal of CancerJanuary 1, 2024Zou C, Shen J, Xu F, Ye Y, Wu Y, Xu S.

(16) One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoidsNature communicationsAugust 17, 2023Geurts MH, Gandhi S, Boretto MG, Akkerman N, Derks LLM, van Son G, Celotti M, Harshuk-Shabso S, Peci F, Begthel H, et al.

(17) Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanismsThe Journal of biological chemistryAugust 1, 2023Hogstrom JM, Cruz KA, Selfors LM, Ward MN, Mehta TS, Kanarek N, Philips J, Dialani V, Wulf G, Collins LC, et al.

(18) Paecilomycone Inhibits Quorum Sensing in Gram-Negative BacteriaMicrobiology SpectrumApril 13, 2023Wouter A. G. Beenker, Jelmer Hoeksma, Marie Bannier-Hélaouët, Hans Clevers, Jeroen den Hertogorganoids were dissociated from the Cultrex basement membrane extract (BME) (R&D Biosystems, Bio-Techne; 3533-001-02) using dispase (Thermo Fisher Scientific; 17105-041) for 30 min at 37°C. Then, organoids were washed

(19) Differentiated mouse kidney tubuloids as a novel in vitro model to study collecting duct physiologyFrontiers in cell and developmental biologyJanuary 1, 2023Olde Hanhof CJA, Dilmen E, Yousef Yengej FA, Latta F, Ammerlaan CME, Schreurs J, Hooijmaijers L, Jansen J, Rookmaaker MB, Orhon I, et al.fragments. Fragments were embedded in Cultrex reduced growth factor Basement Membrane Extract (BME) type 2 (3533-001-02, R&D Systems) and cultured in expansion medium (EM) consisting of basal medium (BM) (advanced DMEM/F12

(20) Novel strategy for primary epithelial cell isolation: Combination of hyaluronidase and collagenase ICell ProliferationJanuary 1, 2023Zhewen Hu, Yiming Chen, Min Gao, Xiaopei Chi, Ying He, Chenguang Zhang, Yue Yang, Yuman Li, Yan Lv, Ying Huang, et al.2611) for cell culture or in organoid‐qualified basement membrane extract (BME) matrix (R&D Systems: 3533‐001‐02) for organoid culture. 2.4 Cell inoculation and passaging According to the requirements of follow‐up

Be the First to Write a Review!

Cultrex RGF Basement Membrane Extract, Type 2 from R&D Systems, a Bio-Techne Brand

Description

R&D Systems, a Bio-Techne Brand

Citations (38)

Reviews

Cultrex RGF Basement Membrane Extract, Type 2 from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map